<DOC>
	<DOC>NCT02036541</DOC>
	<brief_summary>To establish the safety and performance of the AqueSys XEN 45 Glaucoma Implant in eyes with refractory glaucoma.</brief_summary>
	<brief_title>AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma</brief_title>
	<detailed_description>A prospective, multi-center, single arm, open-label clinical trial to evaluate the safety and IOP lowering performance of the AqueSys XEN 45 Glaucoma Implant in refractory glaucoma patients.</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<criteria>Diagnosis of Refractory Glaucoma Maximallytolerated medicated IOP at two preoperative visits of ≥20 mmHg and ≤35 mmHg Visual field mean deviation score of 3 dB or worse Shaffer Angle Grade ≥ 3 Area of free, healthy and mobile conjunctiva in the targeted quadrant Active Neovascular Glaucoma Previous glaucoma shunt/valve in the targeted quadrant History of corneal surgery, opacities or disease/pathology Anticipated need for ocular surgery Nonstudy eye with BCVA of 20/200 or worse</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Glaucoma Implant</keyword>
	<keyword>Trabeculectomy</keyword>
	<keyword>POAG</keyword>
	<keyword>Primary Open Angle Glaucoma</keyword>
	<keyword>Pseudoexfoliation Glaucoma</keyword>
	<keyword>Pigmentary Glaucoma</keyword>
</DOC>